Regulatory approval
Published by the Health Canada. Approved
TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | IDH1 p.R132C | Acute Myeloid Leukemia | Azacitidine, Ivosidenib | |
| HC (1) | IDH1 p.R132G | Acute Myeloid Leukemia | Azacitidine, Ivosidenib | |
| HC (1) | IDH1 p.R132H | Acute Myeloid Leukemia | Azacitidine, Ivosidenib | |
| HC (1) | IDH1 p.R132L | Acute Myeloid Leukemia | Azacitidine, Ivosidenib | |
| HC (1) | IDH1 p.R132S | Acute Myeloid Leukemia | Azacitidine, Ivosidenib | |
| HC (1) | IDH1 p.R132S | Cholangiocarcinoma | Ivosidenib |